Inspire Investing’s Alnylam Pharmaceuticals ALNY Stock Holding History

Inspire Investing’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,797	Closed	-$2.64M	–	795
2023 Q4	$2.64M	Buy	13,797 +339	+3%	+$57.7K	0.29%	75
2023 Q3	$2.38M	Sell	13,458 -6,401	-32%	-$1.22M	0.3%	69
2023 Q2	$3.77M	Buy	19,859 +3,404	+21%	+$675K	0.46%	51
2023 Q1	$3.3M	Buy	16,455 +1,631	+11%	+$343K	0.42%	53
2022 Q4	$3.52M	Buy	14,824 +1,352	+10%	+$288K	0.45%	44
2022 Q3	$2.7M	Sell	13,472 -1,126	-8%	-$215K	0.38%	58
2022 Q2	$2.13M	Sell	14,598 -1,135	-7%	-$161K	0.28%	78
2022 Q1	$2.57M	Sell	15,733 -2,803	-15%	-$427K	0.3%	78
2021 Q4	$3.14M	Buy	18,536 +3,781	+26%	+$703K	0.36%	73
2021 Q3	$2.79M	Buy	+14,755	New	+$2.77M	0.35%	69

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Inspire Investing's ALNY Position: Q1 2024 in Review

Inspire Investing sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 13,797 shares — an estimated $2.64M sold.

Inspire Investing first reported a position in ALNY in Q3 2021 and held it in 10 quarters. The position peaked at $3.77M in Q2 2023. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

Inspire Investing reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Inspire Investing sold 13,797 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $2.64M.
Inspire Investing first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 10 quarters.
Inspire Investing's Alnylam Pharmaceuticals position peaked at $3.77M in Q2 2023.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Inspire Investing's 13F filing for Q1 2024, filed 7 May 2024.